"Trumpflation" Is Real -- and Getting Worse. Here Are 2 Stocks That Turn Rising Prices Into Rising Profits.
The Consumer Price Index rose 3.4% year-over-year in July, driven by energy, electricity, and food price increases. The Trump administration's policies have contributed to inflation, according to the Congressional Budget Office. McKesson (MCK) and Cencora (COR) are pharmaceutical distributors with contracts that may benefit from certain drug price increases. McKesson reported $403.4B in fiscal 2026 revenue and raised its full-year EPS forecast. Cencora generated $321.3B in fiscal 2025 revenue an
How this was made
The 30-second read
Why it matters
Both companies posted earnings beats and raised guidance, suggesting they can capitalize on higher drug prices.
Market read
Earnings beats and raised forecasts for MCK and COR provide a timely trade idea in an inflationary environment.
What to watch
Rising transportation and labor costs may offset inflation‑linked revenue gains.
Background
The article links recent U.S. CPI inflation data to a strategic play on drug distributors with inflation‑linked contracts.
Ticker impact
McKesson reported Q1 2027 revenue up 8% and raised full-year adjusted EPS forecast to $44.20‑$45.00.
Potential short‑term price appreciation as investors price in higher earnings.
Strong revenue growth, EPS beat, and upward guidance in a high‑inflation environment.
Cencora posted Q2 revenue up 3.8% and lifted full‑year adjusted EPS outlook to $17.65‑$17.90.
Likely modest upside as the market digests higher EPS expectations.
Revenue growth and EPS raise reinforce the inflation‑play thesis.
Market effects
Pharmaceutical distribution may benefit from inflation‑linked contracts, highlighting a niche within healthcare.
U.S. healthcare sector could see relative strength versus broader market amid rising CPI.
Shows how inflation dynamics can create winners in non‑commodity sectors worldwide.
Counterpoint
Higher drug prices could eventually pressure margins if regulatory caps tighten, limiting upside.
Key entities
- CompanyMcKesson
Pharmaceutical distributor with inflation‑adjusted contracts.
- CompanyCencora
Pharmaceutical distributor similarly positioned.
